NASDAQ:CFRX
Delisted
ContraFect Corporation Stock News
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update
12:30pm, Monday, 15'th Nov 2021 Intrado Digital Media
YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2021.
ContraFect Corporation (CFRX) Probability Sentiment
01:00am, Monday, 15'th Nov 2021 GEO Investing
Contrafect Corporation (NASDAQ:CFRX) Probability Sentiment SUMMARY Researchers have struggled with the problem of antibiotic resistance to bloodstream infection treatments for the past two decades. Approximately 70% of bacteria have developed a measure of resistance to at least one existing antibiotic. Yet because of robust antibiotic research 70 years ago, doctors []
ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients
07:30am, Tuesday, 26'th Oct 2021
YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA
Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding of Exebacase in Treating Staphylococcus aureus Bacteremia, Including Multidrug-Resistant MRSA Data B
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
07:30am, Wednesday, 22'nd Sep 2021
YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DL
ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market
08:00am, Wednesday, 15'th Sep 2021
CFRX is developing a medicine to treat bacterial infections without using an antibiotic. Phase 2 trials have shown outstanding data against MRSA infections, and reduced hospital time.
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
07:30am, Friday, 13'th Aug 2021
Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company's DLA portfolio
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
07:31am, Monday, 19'th Jul 2021
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
07:30am, Monday, 19'th Jul 2021
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
07:31am, Thursday, 17'th Jun 2021
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
07:30am, Thursday, 17'th Jun 2021
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA
Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
07:30am, Friday, 14'th May 2021
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
07:30am, Monday, 03'rd May 2021
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs
ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
06:30pm, Thursday, 15'th Apr 2021
YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DL